BackFreeline Therapeutics Holdings plc Overview

Freeline Therapeutics Holdings plc Current Cash

Track Freeline Therapeutics Holdings plc's current cash ($29M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$29.45M
55.27% YoYΔ $-36.40M vs prior year quarter

Peer trimmed avg / median

Loading

Freeline Therapeutics Holdings plc Current Cash History

Loading

Freeline Therapeutics Holdings plc vs. peers: Current Cash Comparison

Loading

Freeline Therapeutics Holdings plc Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Freeline Therapeutics Holdings plc (FRLN) FAQ

As of the most recent data (September 2023), FRLN shows a current cash of $29M. That compares with $66M in the prior-year period — down 55.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FRLN's current cash is now $29M (was $66M) — a 55.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Freeline Therapeutics Holdings plc is outperforming or lagging.

Tracking FRLN's current cash over time shows whether Freeline Therapeutics Holdings plc is scaling, shrinking, or reshaping that part of the business. The current reading is $29M That compares with $66M in the prior-year period — down 55.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Freeline Therapeutics Holdings plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $29M) with ownership activity and broader fundamentals.

Freeline Therapeutics Holdings plc's current cash is $29M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.